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Abstract
Background
International human migration has been rapidly growing. Migrants coming from low and mid-
dle income countries continue to be considerably vulnerable and at higher risk for infectious
diseases, namely HIV (Human Immunodeficiency Virus) and tuberculosis (TB). In Europe,
the number of patients with HIV-TB co-infection has been increasing and migration could be
one of the potential driving forces.
Objective
This systematic review aims to improve the understanding on the burden of HIV-TB co-
infection among migrants in Europe and to assess whether these populations are particu-
larly vulnerable to this co-infection compared to nationals.
Design
MEDLINE®, Web of Science® and Scopus® databases were searched from March to April
2016 using combinations of keywords. Titles and abstracts were screened and studies
meeting the inclusion criteria proceeded for full-text revision. These articles were then
selected for data extraction on the prevalence, incidence and mortality.
Results
The majority of HIV-TB prevalence data reported in the analysed studies, including extrapul-
monary/disseminated TB forms, was higher among migrant vs. nationals, some of the stud-
ies even showing increasing trends over time. Additionally, while HIV-TB incidence rates
have decreased among migrants and nationals, migrants are still at a higher risk for this co-
infection. Migrants with HIV-TB co-infection were also more prone to unsuccessful treat-
ment outcomes, death and drug resistant TB. However, contradicting results also showed
lower mortality compared to nationals.
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Conclusions
Overall, a disproportionate vulnerability of migrants to acquire the HIV-TB co-infection was
observed across studies. Such vulnerability has been associated to low socioeconomic sta-
tus, poor living conditions and limited access to healthcare. Adequate social support, early
detection, appropriate treatment, and adequate access to healthcare are key improvements
to tackle HIV-TB co-infection among these populations.
Introduction
The number of international human migratory movements worldwide has been growing over
the past fifteen years, reaching 244 million in 2015 [1]. Since the 1960s, a steady increase in the
number of international migrants coming to and living in Europe has been recorded [2].
Migration is, therefore, recognized as a key component of population change in Europe [3]. In
2015, 1,046,599 migrants arrived to Europe [2], and 76 million international migrants were
residing in Europe, a huge increase compared with the year 2000 (56 million) [1].
Due to these increasing numbers, and regardless of the abiding movements and recent
social awareness for the human crisis affecting Europe, migrants remain among the most vul-
nerable members of the European societies [1], and can be at risk for diseases, including infec-
tious diseases, due to poor living conditions or other disparities [3]. In fact, in the European
Union, migrant populations are at a greater risk of HIV and/or TB acquisition than the general
population [4].
HIV and TB have been influencing each other’s natural history and pathogenesis over time,
enhancing the magnitude of HIV-TB co-infection epidemic [5]. HIV infection is the strongest
known risk factor for developing active TB, which is also the most common opportunistic dis-
ease among HIV-infected patients [6]. People living with HIV/AIDS (Acquired Immunodefi-
ciency Syndrome) and infected with Mycobacterium tuberculosis (latent TB) are at twenty-
times greater risk of developing active TB [6,7], and the intersection of both diseases contrib-
utes to a significant higher morbidity and mortality [6].
Globalization and migration from endemic zones have been considered a major drive in
the global spread of HIV-TB co-infection [8]. In the European Region of the World Health
Organization (WHO), the number of patients with HIV-TB co-infection increased between
2008 and 2014 [9], which some authors attributed partially to migration [10]. Social, economic
and political factors in the origin and destination countries influence the risk of migrant popu-
lations to HIV acquisition—poverty, separation from sexual partners, different social and cul-
tural norms, language barriers, substandard living and exploitative working conditions,
including sexual violence—force many migrants to engage into risky behaviours, increasing
the risk for acquiring the infection. Moreover, living and working conditions in the host coun-
try (access to health services and social protection), travelling journey to Europe (higher risk
in crowded transport vehicles with poorly ventilated spaces plus unhealthy conditions in many
migrant camps across the journey), TB incidence in their country of origin and previous con-
tact with an infectious case, are determinant factors for TB infection among migrants [11].
Many countries have made considerable progress in addressing HIV-TB co-infection, but
many global targets have not been reached yet [5]. Despite the importance of TB and HIV as
public health problems in the European Region of the WHO [7,12], data available is limited on
the risk factors for HIV-TB co-infection [12] and the case-reporting is often incomplete [13].
The available information on the HIV-TB co-infection burden among migrants living in
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Europe is still limited. This information is crucial to provide a comprehensive view to inform
policies and improve adequate care and support to these populations. In this study, a system-
atic review of literature was conducted aiming to improve the understanding of the burden of
HIV-TB co-infection among migrants in Europe and to compare the prevalence, incidence
and mortality in this population with nationals in Europe. This systematic review is one of the
first addressing specifically on the burden of this co-infection among migrants and the results
obtained clearly demonstrate the importance for the national HIV-TB programs to address
this reality systematically in order to control the predicted impact on these vulnerable popula-
tions and on the national control programs.
Materials and methods
A combination of key words and/or Medical Subject Headings (MeSH) terms was used to find
relevant studies. Our search was defined, using specific tools available in the searched data-
bases, to retrieve publications between 2000 and 2016. Only articles with abstracts and written
in English, Spanish, French or Portuguese were considered. Books or book chapters, com-
ments, editorials, reviews, guidelines, reports, newspaper articles and case-studies were not
included.
The electronic databases MEDLINE1, Web of Science1 and Scopus1 were systematically
searched between March and April 2016 for original articles using search terms presented in
S1 Table. MEDLINE1 was the first choice since it is one of the largest bibliographic databases
focused on medical related fields [14,15]. Scopus1 was also searched as it includes also
EMBASE1 database additionally to MEDLINE1 content, plus other journals indirectly related
to the medical field [16]. Web of Science1 (via https://www.webofknowledge.com) was also
included due to its coverage on medical or medically related journals missed by Pubmed and
EMBASE1 [17].
The titles and abstracts of all documents retrieved were screened by one main reviewer
(Ana Maria Tavares—AMT). A second reviewer (Inês Fronteira—IF) performed screening in
a random sample of retrieved documents—the minimum sample size was calculated in Open-
Epi platform (in www.openepi.com) using an anticipated frequency of 7.6%, for a 95% Confi-
dence Interval (CI)—, in order to access sensibility and specificity of the inclusion criteria [18].
Disagreement between reviewers concerning this sample of documents was solved through
reanalysis of the respective titles/abstracts and consensus.
Only the scientific papers meeting the following inclusion criteria were selected: 1) the stud-
ied population includes migrant subjects infected with HIV and TB, 2) it provides measures of
prevalence, incidence and/or mortality; 3) the study and/or studied population was sampled in
one or more European countries (of the 51 independent states [19]); 4) it is an observational
study. The following exclusion criteria were defined: 1) articles in which the studied popula-
tion does not mention human migrants (immigrants, emigrants and others); 2) articles with
migrants not living in European countries; 3) articles about infectious diseases other than HIV
and/or pulmonary tuberculosis; 4) articles about HIV or TB only, separately; 5) articles about
co-infections other than HIV-TB co-infection; 6) articles without the outcomes of interest
(prevalence, incidence and/or mortality).
After screening for titles and abstracts, the selected articles proceeded for fulltext review, in
which, only articles meeting all inclusion criteria and not meeting any exclusion criteria were
considered for data extraction. The data extraction process was performed by one researcher
(AMT). Data on the prevalence, incidence and mortality associated with co-infection in
migrants and nationals (when available) were extracted. Prevalence of extrapulmonary and/or
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disseminated TB and drug resistant TB among HIV-TB co-infection cases were also consid-
ered, as well as measures of risk and association related to HIV-TB co-infection in migrants.
For this systematic review no protocol was registered and no quality scoring system was
applied.
Results
A total of 746 articles were retrieved from databases (S1 Table) and, after removing duplicates
(n = 251), 495 articles remained for title and abstract screening by one main reviewer (AMT).
Of these, a sample of 214 articles was randomly selected for titles and abstracts screening by a
second reviewer (IF).
During screening, 453 articles were excluded: 292 articles were eliminated after applying
the inclusion and exclusion criteria, 54 articles were written in other foreign languages not
considered, 85 documents were publication types not considered for this review, and 22 docu-
ments lacked an abstract available for screening. After screening, 42 articles remained for full-
text revision and, after applying inclusion and exclusion criteria, only 27 articles were
retrieved for data extraction. The full details of the articles selection process is summarised in
Fig 1.
Characteristics of the studies
The studies included were published between 2003 and 2016, while the sampling for those
studies was conducted between 1984 and 2013. Eight European countries were represented:
eleven studies conducted in Spain [20–30], five studies in Italy [31–35], three studies in France
[36–38], two studies in Portugal [39,40], Germany [41,42], and United Kingdom (UK) [43,44],
and one study in Switzerland [45] and The Netherlands [46] (Table 1).
The main study design was retrospective—eight studies [22–24,28,29,39,40,42]—followed
by six prospective/cohort studies [34,36,37,41,45,46] (one of them also multicentric [34]), two
population-based studies [31,43], one quasi-experimental study [26] and one multicentric
study [35]. The remaining studies did not mention the adopted study design
[20,21,25,27,30,32,33,38,44] (Table 1). Four studies provided data from national registries
[28,33,39,43].
The sample size ranged between studies from 69 [22] to 72580 subjects [36,37]. The
included subjects varied between studies: some studies included patients diagnosed with TB
[27,28,32,38–40], HIV/AIDS [20,24,36,37,41,46], or HIV-TB co-infection [30,33,34,43]. Other
studies included immigrant patients [21,35], immigrant/foreign-born TB patients
[26,29,39,42], immigrant/foreign-born HIV patients [22,23,25,45,46], and immigrant/foreign-
born HIV-TB patients [42].
Considering the region of origin, Africa was predominant, with higher percentages of
immigrants born in Africa in 10 retrieved studies [25,30,33,35–37,39,40,42,46], followed by
Latin America [20–22,26,27], and Western/Eastern Europe [38,45] (Table 1).
Prevalence of HIV-TB co-infection among migrants
Prevalence measures of HIV-TB co-infection were reported in 20 of the 27 studies selected in
this review (Table 2).
Among these, 10 studies reported prevalence numbers of HIV-TB co-infection in immi-
grants and nationals [20,21,24,27,32,37–40,44]. Prevalence of co-infection was higher among
immigrants than among nationals in 7 studies conducted in France, Portugal, Spain and UK
[20,24,37–40,44]—range of 2.8%-85% among migrants vs. 2.3%-30.8% among nationals
(Table 2)—, of which, one study was based on national registries from Portugal (2008–2012)
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[39]. Contradictory results were observed in 3 studies [21,27,32]—ranging between 6%-6.8%
among migrants vs. 2.3%-37% among nationals (Table 2). Studies including only migrant
patients, most conducted in Spain, showed prevalences of HIV-TB co-infection ranging from
1% to 76.6% [22,23,25,26,29,31,35,42,45,46] (Table 2).
Increases in prevalence of HIV-TB co-infection among migrants during data collection
periods were reported in 3 studies. In the city of Barcelona, a significant increase was observed
in the prevalence of HIV-TB co-infection in migrants, from 6.5% in 1994 to 37.1% in 2004,
contrarily to nationals, in which a significant decrease has been observed [24]. Another study
in Barcelona also reported a small increase in the prevalence of HIV-TB co-infection among
migrants from 8.6% in 2000–2002 to 9.3% in 2003–2005 [26]. This increasing trend was also
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0185526.g001
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Table 1. Main characteristics of the studies included in the review.
First author Year Year of data
collection




Abgrall et al. (a)
[37]
2010 1997–2008 France HIV patients 72580 France: 58 089 (80%); SSA: 9095
(12.5%); Others: 5396 (7.5%)
Prospective
cohort study
Abgrall et al. (b)
[36]
2010 1997–2008 France HIV patients 72580 France: 58 089 (80%); SSA: 9095





2006 2001 Italy New TB immigrant
patients
640 EE: 43 (25%); Africa: 89 (52%); LA: 20
(12%); Asia: 13 (8%)
Population-based
study
Brindicci et al.[32] 2016 2005–2013 Italy (BAT
Province)
TB patients 129 Italy: 85; Immigrants: 44 immigrants
[EE: 25 (22.7%); SSA: 10 (22.7%);
NA: 6 (13.6%)]
-
Camoni et al.[33] 2012 1993–2010 Italy HIV-TB patients 4075 Italy: 2685 (65.9%); Immigrants: 1390
(34.1%) (Africa: 55.3%; SA: 29.0%;




2009 2004–2006 Spain HIV patients 2507 Spain: 1793 (71.5%); WE: 93 (3.7%);
EE: 42 (1.7%); SSA: 145 (5.8%); NA:
34 (1,4%); LA/Caribbean: 400 (16.0%)
-
Diz et al.[21] 2007 1990–2002 Spain Immigrant patients 1353 LA: 55%; Africa (37%). -
Ennemoser et al.
[42]
2015 1994–2013 Germany HIV-TB/TB
immigrant patients
47; 46 Africa: 53; Asia: 34; EE: 6 Retrospective
study




69 LA: 38; SSA: 23; EE: 7; NA: 1 Retrospective
study
Girardi et al.,[34] 2012 - Italy HIV-TB patients 246 Italy: 162; Foreign-born: 84 Multicenter
prospective study
Karo et al.[41] 2014 2001–2011 Germany HIV patients 11693 - Cohort study
Kesselring et al.
[46]
2010 1996–2008 Netherlands Foreign-born HIV
patients
6057 WE/North America: 3947 (65%); SSA:
989 (16%); Southeast Asia: 237 (4%);









371 LA: 197 (53.1%); SSA: 91 (24.5%);
Caribbean: 32 (8.6%); EE/Central
Asia: 20 (5.4%); Central-WE: 20
(5.4%); NA/Middle East: 9 (2.4%);
North America: 1 (0.3%); South and
Southeast Asia: 1 (0.3%)
Retrospective
study
Martin et al.[24] 2011 1994–2005 Spain
(Barcelona)





2012 1995–2008 France new TB patients 14610 France: 7481; Foreign-born: 7129
[SSA: 2770 (39%); Maghreb: 2101
(30%); Asia: 1243 (17%); Europe: 695
(9.8%) (EE/Balkans: 308 (44%);
Central Europe: 53 (8%); WE: 334
(48%))].
-




78 SSA: 41 (56.9%); SA: 19 (26.4%);
Others: 18 (16.7%)
-










2000–2002 –LA: 202 (35.3%); India/
Pakistan: 136 (23.8%); NA: 92
(16.1%); Others: 142 (24.8%). 2003–
2005 –LA: 152 (39.2%); India/
Pakistan: 112 (28.9%); NA: 42





Paulino et al.[39] 2016 2008–2012 Portugal native-born TB
patients; foreign-
born TB patients
4131; 2009 Nationals: 4131; Foreign-born: 2009
[Africa: 1484 (73.9%); SA: 209
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observed in the UK in the number of HIV-TB cases either among persons with insecure immi-
gration or seeking asylum, from 45 in 2001 to 78 in 2002 [44].
Ten studies reported prevalence of HIV-TB co-infection per migrants’ region of origin [20–
24,29,35,42,45,46], namely African [20–24,35,42,45,46], Latin American [20–24,29,35], Euro-
pean [20,22,23,35], and Asian regions [24,35]. The highest HIV-TB percentages were observed
in migrants from African regions (range 1%-76.6%) [42,45], particularly migrants from SSA
(range 1%-50% [24,45]), followed by migrants from Europe [3.2% (Western Europe) - 42.8%
(Eastern Europe) [20,22]], from Asia (36.4% from South Asia/East Asia/Pacific [24]), and from
Latin America (range 2% to 31.7% [21,24]) (Table 2).
Concerning the prevalence of various TB forms among HIV infected patients, seven studies
reported extrapulmonary and/or disseminated TB cases [20–23,25,30,35], of which, three, all
conducted in Spain, compared prevalence between migrants and nationals. Higher percentage
of extrapulmonary TB was reported among HIV-infected migrants (75.8% vs. 68.4% in nation-
als) from 1984 to 2000, however non-significantly [30]. Contradictory results were observed
between 1990 and 2002, with a higher rate of disseminated TB among HIV-infected nationals
(33%) [21]. However, between 2004 and 2006 a significantly higher percentage of extrapul-
monary TB was observed among HIV-infected migrants from Eastern Europe/Russia, Sub-
Table 1. (Continued)
First author Year Year of data
collection













Ramos et al.[27] 2004 1999–2002 Spain (Elche) TB patients 105 Nationals: 83; Immigrants: 22
[Morocco: 5 (22.7%); SA: 9 (40.9%);
EE: 4 (18,2%); SSA: 4 (18,2%)]
-
Rice et al.[43] 2013 2002–2010 England and
Wales








TB patients 1013 Nationals: 765; Immigrants: 248 [Cape
Verde: 107 (43,1%); Angola: 60
(24,2%); Guinea: 40 (16,1%); S.Tome
and Principe: 21 (8,5%); Mozambique:






2015 2012 Spain TB patients 5880 Nationals: 3992; Foreign-born: 1888 Retrospective
study
Scotto et al.[35] 2006 2003 Italy immigrant patients 2392 Africa: 145 (48.3%); Asia: 60 (20%);




2003 1989–2001 Switzerland HIV immigrant
patients
11872 Northwestern Europe: 9420 (79%);










94 Asia: 49; LA: 45 Retrospective
descriptive study
Velasco et al.[30] 2008 1984–2000 Spain
(Madrid)
HIV-TB patients 1284 Nationals: 1185; Immigrants: 99
[Africa: 62.6%; Central/SA: 16.2%; EE:
4%; WE: 14%; Asia: 3%].
-
BAT—Barletta-Andria-Trani; EE- Eastern Europe; LA—Latin America; NA—North Africa; SA—South America; Sub-Saharan Africa—SSA; WE—Western
Europe
https://doi.org/10.1371/journal.pone.0185526.t001
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Saharan Africa, Western Europe, North Africa, and Latin America/Caribbean (9.5%, 5.5%,
4.3%, 2.9%, and 2%, respectively vs. 2.5% in nationals) [20].
In Italy, a study including only migrants reported 13% of lymph node TB, 9.7% of multiple
localization TB; 3.2% of osteoarticular TB, 3.2% of central nervous system TB, and 3.2% of
intestinal TB in 2003 among HIV-TB infected migrants [35]. In Spain, studies performed in
Alicante and Madrid, reported similar figures of disseminated TB—5.8% and 7.7%,
Table 2. Prevalence of HIV-TB co-infection among national and migrant patients.




Abgrall et al. (a)
[37]
2010 France HIV patients 1394 (2.4%) 1231 (8.5%)
Baussano et al.[31] 2006 Italy New TB immigrant
patients
NA 32 (5%)
Brindicci et al.[32] 2016 Italy (BAT
Province)





2009 Spain HIV patients 41 (2.3%) 4 (2.8%) from SSA; 12 (3%) from LA/Caribbean; 3 (3.2%) from
WE
Diz et al.[21] 2007 Spain Immigrant patients 37% 6% (p<0.001) (14% from Africa, 2% from LA)
Ennemoser et al.
[42]
2015 Germany HIV-TB and TB immigrant
patients
NA 47 (51%): (higher proportion of patients from Africa [36
(76.6%]
Eszol et al.[22] 2009 Spain
(Alicante)








2012 Spain (Madrid) Immigrant HIV patients NA 36 (9.7%): 13.2% from SSA, 33.3% from North Africa/Middle
East, 6.1% from LA, 6.3% from Caribbean, 20% from Central/
WE, 10% from EE/Central Asia




37.1% (p = 0.02): 50% from North Africa/Middle East, 50%
from SSA, 31.7% from LA/Caribbean, 36.4% from South Asia/




2012 France New TB patients 6.5% 11%
Ortega et al.[25] 2007 Spain (Madrid) Foreign-born HIV patients NA 16 (20.5%)
Ospina et al.[26] 2012 Spain
(Barcelona)
Foreign-born TB patients NA 49 (8.6%) in 2000–2002, 36 (9.3%) in 2003–2005
Paulino et al.[39] 2016 Portugal Native and foreign-born
TB patients











Ramos et al.[27] 2004 Spain (Elche) TB patients 12 (14.5%)
(p = 0.4)
2 (9.1%) (p = 0.4)
Rifes and Villar[40] 2003 Portugal
(Amadora)
TB patients 182 (18%) 66 (26.6%)
Scotto et al.[35] 2006 Italy Immigrant patients NA 31 (10.3%): 18 from Africa, 8 from LA, 3 from EE, 2 from Asia,
Staehelin et al.[45] 2003 Switzerland HIV immigrant patients NA 7 (1%) (from SSA)




NA 5 (11.1%) (from LA)
BAT—Barletta-Andria-Trani; EE- Eastern Europe; NA- not applicable; SSA- Sub-Saharan Africa; LA—Latin America; WE—Western Europe
https://doi.org/10.1371/journal.pone.0185526.t002
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respectively—, from 2000 to 2006 [22,25]. Another study in Madrid reported 37.1% cases of
disseminated TB, 14.3% cases of ganglionar TB, 5.7% cases of tuberculous meningitis and
2.9% cases of pleural TB from 1992 to 2009 [23].
Among the included studies, 4 analysed proportion of migrants among co-infected cases
[30,33,41,43]: two showing higher percentages of immigrants among co-infected patients
[41,43], and two showing increasing trends in the proportion of migrants among co-infected
patients during data collection [30,33].
Only a study in France reported prevalence of drug resistant TB among HIV-TB co-
infected migrants and nationals, with a significantly higher percentage of resistance to strepto-
mycin, isoniazid, rifampicin among foreign born patients compared to nationals (12.5%,
10.4% and 3.6%, vs. 8.0%, 6.7% and 1.2%, respectively) [38].
Incidence of HIV-TB co-infection among migrants
Incidence rates of HIV-TB co-infection among migrants were reported in 6 studies
[24,33,36,37,41,46]. Two studies conducted in France by the same authors on the same
patients’ cohort reported a higher incidence rate among migrants—1.03/100 person-years;
95% CI: 0.95–1.11 vs. 0.28/100 person-years; 95% CI: 0.26–0.30 in nationals [36,37], despite of
a significantly higher proportion of incident cases among nationals—564 (55.6%) vs. 330
(48.6%) in migrants—observed between 1997 and 2008 in one of the studies [37]. In the same
two studies, the adjusted incidence rates showed an increase in the incidence of HIV-TB co-
infection either among migrants (0.77/100 person-years in 1997; 1.60/100 in 2000; 1.24/100
person-years in 2002; 1.94/100 in 2008) and among nationals (0.46/100 person-years in 1997
person-years; 0.57/100 in 2000; 0.64/100 in 2002; 0.86/100 in 2008) during the study period
[36,37]. Similarly, in Italy a higher incidence rate was observed among migrants—2.97/100
000 person years vs. 0.11/100 000 person years among nationals—, with a decrease over time
among migrants (5.16/100 000 person-years in 1993 to 1.20/100 000 person-years in 2010) and
nationals (0.17 /100 000 person-years in 1993 to 0.05/100 000 person-years in 2010) [33]. In
England and Wales, HIV-TB incidence was higher among foreign-born patients in 2002 (42.5/
1000 person-years vs. 8.6/1000 person-years among nationals) and 2010 (10.9/1000 person-
years vs. 83.3/1000 person-years among nationals), also showing a decline in the HIV-TB inci-
dence between 2002 and 2010 either for foreign-born (decline in 74.3%) or national patients
(decline in 61.2%) [43]. A study conducted in Barcelona also showed higher incidence rates
among male immigrants aged 29–49 years (15.8 vs. 12.7/100000 national inhabitants aged 20–
29 years; 41.8 vs. 37.5/100000 national inhabitants aged 30–39 years; 33.4 vs. 14.7/100000
national inhabitants aged 40–49 years) and female immigrants aged 40–50 years old (7.9 vs.
1.3/100000 national inhabitants aged 40–49 years; 4.7 vs. 0.4/100000 national inhabitants aged
50–59 years), with an average rate decrease of 20% per year between 1994 and 2005 among
both nationals and immigrants [24].
Three studies compared the incidence rates within migrants’ region of origin. A study con-
ducted in Germany reported a significantly higher incidence density rate of HIV-TB co-infec-
tion in patients from Sub-Saharan Africa (1.20/100 vs. 0.21/100 person years in nationals) and
other countries (0.52/100 vs. 0.21/100 person years in nationals) between 2001 and 2011 [41].
Similarly, in a study conducted in The Netherlands, the cumulative TB incidence after 7 years
of combined antiretroviral therapy (cART) treatment was higher among HIV-positive patients
from Sub-Saharan Africa compared with HIV-TB patients from Western Europe/North
America (4.5% vs. 0.5%) [46]. A study conducted on the region of Piedmont, Italy, with new
cases of TB among immigrant patients, showed annual incidence rate ratios of HIV-TB co-
infection among patients from low prevalence countries of 179.3/100 000; 95% CI: 88.7–269.9
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population among patients < 50 years, and 681.6/100 000; 95% CI: 212.7–1150.5 population
among patients50 years. Among patients from higher prevalence countries the annual inci-
dence rate ratios were of 1139.5/100 000; 95% CI 403.1–1857.9 population among patients
<50 years, and no incident cases among patients50 years [31].
Mortality and survival among HIV-TB infected migrants
Mortality and survival measures were reported in four studies [28,30,34,41], all with data on
migrants and nationals. A study conducted in Germany from 2001 to 2011 observed a signifi-
cantly lower survival in co-infected patients from Sub-Saharan Africa, compared to co-infected
nationals (93% vs. 99% among nationals) [41]. However, contrasting results were shown previ-
ously in a study conducted in Spain from 1984 to 2000, with a significantly better survival of
co-infected immigrants (median 8.7 vs. 5.4 years among nationals) and also a significantly
lower mortality rate (0.42 vs. 0.45 among nationals) [30]. Another study conducted in Spain in
2012 also showed lower percentage of deaths among immigrant HIV-TB patients (6.99% vs.
8.79% among nationals) [28]. Similarly, a study from Italy reported a lower percentage of
deaths among co-infected foreign-born patients (8.3% vs. 17.9% among nationals), however
without statistical significance [34].
Indicators and trends of risk and association
Eleven studies reported measures of risk and/or association [22,24,28,31,34,36–39,41,46]. Two
studies performed in France between 1997 and 2008 using the same patients’ cohort observed
twice more risk of TB among HIV-infected migrants—adjusted risk ratio (aRR) = 2.01; 95%
CI: 1.79–2.26 [36,37]. An increased risk of HIV-TB from 2000/2001 to 2008 among nationals
and migrants was also observed in one of the studies—aRR = 1.85; 95% CI: 1.27–2.70 [37].
Also, a non-significant 21% risk increase among nationals (aRR = 1.21, 95% CI: 0.86–1.70)
and a significant 49% risk increase among migrants (aRR = 1.49, 95% CI 1.04–2.14) were
observed from 2002–2003 to 2008 in the other study [36].
Three studies evaluated the risk of HIV-TB acquisition considering the regions of origin
[31,41,46]. A study conducted in The Netherlands between 1996 and 2008 observed a 5-fold
higher risk of HIV-TB among immigrants born in Sub-Saharan Africa compared to immi-
grants from Western Europe or North America (Hazard ratio (HR) = 5.08, 95% CI: 2.22–
11.60) [46]. Similarly, a study conducted in Germany between 2001 and 2011 showed that
being born in Sub-Saharan Africa significantly rendered a higher risk for HIV-TB [HR = 4.05;
95% CI: 1.87–8.78 among patients who never started combination antiretroviral therapy
(cART) and HR = 5.15; 95% CI 2.76–9.60 among patients on cART], as well as being born in
other countries than Germany (HR = 2.22; 95% CI 1.18–4.20 among patients on cART) [41].
A study in the Italian region of Piedmont referred that an HIV-positive status appeared to pro-
mote TB among immigrants from low and high prevalence countries, with a higher risk
among those originating from low prevalence countries—incidence rate ratio of 51.9; 95% CI:
30.2–89.4 vs. 11.4; 95% CI 5.8–22.5 among those originating from high prevalence countries
[31].
Four studies reported associations between migration and HIV-TB co-infection. A study
conducted in Barcelona from 1994 to 2005 observed an association between being born in
Sub-Saharan Africa and having TB and AIDS defining illness—adjusted odds ratio (aOR) =
2.2; 95% CI: 1.2–4.6 [24]. However, another study from Spain, performed between 2000 and
2006, showed a strong significant association of HIV-TB co-infection with being born in East-
ern Europe—OR = 8.55; IC 95%: 1.5–49.4—and a negative association with being born in
Latin America—OR = 0.09; 95% CI: 0.01–0.89 [22]. In a study in Portugal conducted between
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2008 and 2012, the odds of being a foreign-born TB case among the HIV-positive population
was approximately double compared to nationals—OR = 2.137; IC 95%: 1.65–2.77 [39]. More-
over, the abovementioned study conducted in France from 1997 to 2008 observed a higher
risk for HIV-TB co-infection among migrants from Sub-Saharan Africa—adjusted risk ratio
(aRR): 2.16 (95% CI: 1.88–2.48)—and other regions—aRR: 1.83 (95% CI 1.57–2.14)—, com-
pared to nationals [37].
A study conducted in Italy referred an association between being a migrant with HIV-TB
and unsuccessful treatment outcomes (i.e. lost to follow-up, failure, being transferred out,
default)—OR = 3.38, 95% CI 1.38–8.29) [34]. Similarly, in a study in Spain a higher association
with potentially unsuccessful outcomes and death was observed among co-infected foreign-
born patients than in nationals (OR = 1.7; 95% CI: 1.15–2.60 vs. OR = 1.6; 95% CI: 1.09–2.29
and OR = 3.2; 95% CI: 1.53–6.76 vs. OR = 2.7; 95% CI: 1.63–4.54, respectively) [28]. In a study
conducted in France, an association between being a migrant with HIV-TB and having TB
resistance to streptomycin (OR = 1.6; 95% CI: 1.3–2.0), isoniazid (OR = 1.6; 95% CI: 1.3–2.1)
and rifampicin (OR: 2.9; 95% CI: 1.9–4.6) was also observed, whereas co-infection in French-
born patients was only associated with rifampicin resistance (OR: 4.7; 95% CI: 2.1–10.5) [38].
Discussion
In this systematic review we investigated the burden of HIV-TB co-infection among migrants
comparatively to national populations.
The results have shown that migrant populations are disproportionately affected by
HIV-TB co-infection when compared to nationals. The majority of the studies reporting prev-
alence of HIV-TB co-infection showed significantly higher values among migrants compared
to nationals, and some studies also showed a higher prevalence of extrapulmonary/dissemi-
nated TB among HIV-infected migrants. Moreover, in all the studies in which prevalence fluc-
tuations of HIV-TB co-infection were shown, most of them conducted in Spain, a more
pronounced increasing trend was observed among migrants, whereas a decreasing pattern was
observed in some national populations. These results are in line with a 2017 ECDC report,
describing an increase in the absolute number of patients with HIV-TB co-infection in the
European Region of the WHO from 11652 cases in 2011 to 16380 in 2015 [47]. As previously
described in a systematic review conducted in 2011, the increasing trends of HIV-TB co-infec-
tion might be related to migration, especially in countries such as Spain and Italy [10], which
were also the countries of the majority of our studies. Nevertheless, considering that the com-
parison of HIV-TB prevalences between nationals and migrants was only performed in 10 of
the 20 articles reporting prevalence of HIV-TB co-infection, such findings must be interpreted
with caution, as we cannot disregard that different findings could be observed if more studies
compared prevalence between the two populations.
When considering the country of origin, the highest prevalences were observed in migrants
originating from African regions. It has been documented that HIV epidemic among the com-
munities of sub-Saharan African migrants in Europe partially resembles the magnitude of the
HIV epidemics in their home countries [48]. Also, the described reasons underlying the bur-
den of TB among migrants are the interaction of migration from high TB burden countries
and the reactivation in host countries [49]. Therefore, these prevalences might be related with
origin from high HIV and TB prevalence countries in Africa, especially those from Sub-Saha-
ran region. However, more data regarding regions of origin could provide a clearer view.
The incidence rates of HIV-TB were also shown to be significantly higher among migrant
populations, as well as the risk for co-infection, affecting especially those from high prevalence
regions, such as Sub-Saharan Africa. In fact, Africa is still the most common origin of
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migration to Europe and since the late 1980s there has been a hastening of emigration from
this region to Europe [50]. Moreover, the prevalence of HIV-TB co-infection is the highest in
the African region [51]. Therefore, it is not unexpected that migrants from Sub-Saharan Africa
were observed to be at higher risk of co-infection in the analysed studies, since HIV co-infec-
tion has been found to be more likely in TB cases originating from Africa [47].
In this review, many studies reported a decrease in the incidence of HIV-TB co-infection
over the data collection period among migrants and nationals. These promising findings may
be interpreted as a success of control and prevention measures in Europe. However, a report
from WHO refers that the incidence of HIV-TB co-infection has been slowly increasing since
1990 in the WHO European Region, being 2.2/100000 population in 2014 [51]. Therefore, no
firm conclusions can yet be drawn based on these findings.
Being a migrant infected with HIV-TB was also associated with unsuccessful outcomes
(treatment failure, being transferred out, and others), death and drug resistant TB, the later
also observed in a previous review by Hargreaves et al. (2016) [52]. These findings are possibly
related with factors influencing patients’ adherence to treatment, such as financial and social
support, medication burden, side effects, stigma, beliefs and poor communication with health
professionals [53]. Some of the studies [28,30,34] also referred that migrants co-infected with
HIV-TB seemed to have lower mortality than nationals with the same co-infection. These
results are quite contradictory in the light of the disproportionate vulnerability of migrants to
HIV-TB observed in the previous results. Similar findings have been documented in a review
by Domnich et al. (2012) and associated with the not yet fully understood and paradoxical
“healthy migrant” effect—migrant populations may present a better health compared to
nationals—, caused by a previous self-selection process prior to migration, in which only
healthier and younger subjects are fit for emigration [54]. This effect would cause better
chances of survival in case of infection, what could explain the lower mortality rates observed
among migrants. However, according to Domnich et al. (2012), the “healthy migrant” effect is
a temporary state that diminishes as time passes after immigration, possibly due to the dispari-
ties in the access to healthcare, and in the socioeconomic status [54]. These are factors that also
might negatively impact the unsuccessful outcomes and TB resistance observed in our study.
Although better survival was observed among migrants in this systematic review, Europe is
one of the world’s regions with higher mortality rates caused by HIV-TB co-infection [55]
and, therefore, it is important to understand the role of migration in HIV-TB associated mor-
tality in European countries.
Methodological heterogeneity was observed in analysed studies, especially regarding study
design, sample size, sampling procedure and epidemiological outcomes. Such differences ren-
dered a challenging interpretation and comparison between studies.
Limitations of this systematic review must be acknowledged. Given the vast existing num-
ber of articles on the HIV, TB and/or migrants subjects, a narrow search strategy was used,
very focused on the objectives of this review. MeSH terms were criteriously selected to be used
in the MEDLINE1 database search, as well as restrictions for titles and abstracts search at Sco-
pus1 database. Broader search terms could have also been used in the search expressions, such
as “vulnerable populations” and “Europe”. We acknowledge that such methodological choices
may imply a loss of comprehensiveness in our search. Also, the outcomes observed in the
selected studies comprised different data collection periods, some of them taking place before
the dawn of the combined antiretroviral therapy in 1996 [56]. In such studies, no distinction
was made between data from pre and post-HAART period. No differences were observed
when comparing the data from studies conducted before and after the introduction of
HAART. Even so, we cannot exclude potential bias in the outcomes assessed in this review.
Moreover, many retrieved studies were conducted on a specific region or city and, therefore,
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lack epidemiological representativeness of the problem in a certain country. In such cases,
only a descriptive synthesis of evidence was possible and the findings must be interpreted only
in the context of the represented region.
In this work we have been able to highlight the disproportionate vulnerability of migrants
to acquire HIV-TB compared to nationals, a clear trend in the majority of the studies included.
Higher prevalence, incidence, unsuccessful outcomes and drug resistance figures were
observed among migrants living in European countries. The low socioeconomic status, the
poor and overcrowded living and working conditions, malnutrition, substance use induced by
marginalization, social exclusion [57], and barriers in the access to health care [58], are well
described factors that may contribute for this disproportion between migrants and nationals.
In order to tackle such inequities, European health systems must keep their efforts on the early
detection and appropriate treatment of these infections among these populations, as well as to
guarantee an adequate access to healthcare and efficient social support. Moreover, policies of
inclusion and integration of these populations in the host society are of utmost importance in
the preventive care of these diseases. Further research should continue on data collection from
national registries on the HIV-TB co-infection among migrants, providing information on the
epidemiological situation of each European country, and also in interventions to improve the
main barriers to health care perceived by migrant patients infected with HIV-TB. Information
on length of stay among migrants was also poorly explored in the included studies of this Sys-
tematic Review. Therefore, future research should also take into account this variable in order
to allow better understanding of how the burden of HIV-TB co-infection varies with time of
residency in the host country. This work highlights the importance for the national HIV-TB
programs to thoroughly address this problem in order to mitigate the impact on these vulnera-
ble populations and on the national control programs.
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